What should I do if I develop resistance to capmatinib?

Capmatinib (Capmatinib) is a treatment for non-small cell lung cancer with a certain mutation. When patients develop resistance to this drug, close cooperation and communication with their doctors is crucial. Patients should promptly report any changes in symptoms to their doctor and follow the doctor's instructions for treatment and follow-up. Gene mutation analysis is performed to determine the specific cause of resistance. This can be achieved by detecting MET gene mutations or abnormalities in other related genes in cells. Understanding genetic mutations can help doctors determine whether treatment options need to be adjusted and choose more appropriate alternatives.

Based on the results of gene mutation analysis, doctors may consider using other targeted therapies to replace capmatinib. Such as some third-generation MET inhibitors or other related targeted drugs. These drugs may have different mechanisms of action on drug-resistant cells, thereby providing better therapeutic effects. In addition to targeted therapies, comprehensive treatment options should also be considered. This includes chemoradiotherapy, surgical resection, radiotherapy, etc., and an individualized treatment plan is developed based on the patient's specific situation. Comprehensive treatment can consider multiple factors to improve treatment effectiveness and reduce the risk of drug resistance.

For patients, participating in relevant clinical trials is also an option to deal with drug resistance. Clinical trials can provide the latest treatment options and provide patients with access to new, effective medicines. Patients can discuss with their doctor whether they are suitable to participate in relevant clinical trials. In addition, actively participating in supportive treatment and maintaining a good lifestyle, such as a balanced diet, moderate exercise, and coping with psychological stress, can also help improve the body's immunity and overall treatment effect.